
1. sci transl med. 2020 may 20;12(544). pii: eaaz5629. doi:
10.1126/scitranslmed.aaz5629.

a double-blind, placebo-controlled phase 1/2a trial genetically attenuated
malaria vaccine pfspz-ga1.

roestenberg m(1)(2), walk j(3)(4), van der boor sc(3), langenberg mcc(1),
hoogerwerf ma(1), janse jj(1), manurung m(1), yap xz(3), garcía af(3), koopman
jpr(1), meij p(5), wessels e(6), teelen k(3), van waardenburg ym(3), van de
vegte-bolmer m(3), van gemert gj(3), visser lg(2), van der ven ajam(4), de mast
q(4), natasha kc(7), abebe y(7), murshedkar t(7), billingsley pf(7), richie
tl(7), sim bkl(7), janse cj(1), hoffman sl(7), khan sm(1), sauerwein rw(8).

author information: 
(1)department parasitology, leiden university medical center, 2333 za leiden, 
netherlands.
(2)department infectious diseases, leiden university medical center, 2333 za
leiden, netherlands.
(3)radboudumc center infectious diseases, department medical microbiology,
radboud university medical center, 6525 ga nijmegen, netherlands.
(4)radboudumc center infectious diseases, department internal medicine,
radboud university medical center, 6525 ga nijmegen, netherlands.
(5)interdivisional gmp facility, department clinical pharmacy toxicology, 
leiden university medical center, 2333 za leiden, netherlands.
(6)department medical microbiology, leiden university medical center, 2333 za 
leiden, netherlands.
(7)sanaria inc., rockville, md 20850, usa.
(8)radboudumc center infectious diseases, department medical microbiology,
radboud university medical center, 6525 ga nijmegen, netherlands.
robert.sauerwein@radboudumc.nl.

immunization attenuated plasmodium sporozoites induce protection against
malaria infection, shown plasmodium falciparum (pf) sporozoites attenuated 
by radiation multiple clinical trials. alternative attenuation strategy
with homogeneous population pf sporozoites (pfspz), genetically
engineered plasmodium berghei sporozoites (spz) lacking genes b9 slarp
induced sterile protection malaria mice. consequently, pfspz-ga1
vaccine, pf identical double knockout (pf∆b9∆slarp), generated a
genetically attenuated malaria parasite vaccine tested safety,
immunogenicity, preliminary efficacy malaria-naïve dutch volunteers.
dose-escalation immunizations 9.0 × 105 pfspz pfspz-ga1 vaccine were
well tolerated without breakthrough blood-stage infection. subsequently, groups
of volunteers immunized three times direct venous inoculation with
cryopreserved pfspz-ga1 vaccine (9.0 × 105 4.5 × 105 pfspz, n = 13 each),
pfspz vaccine (radiation-attenuated pfspz, 4.5 × 105 pfspz, n = 13), normal
saline placebo 8-week intervals, followed exposure mosquito bite
controlled human malaria infection (chmi). chmi, 3 25 volunteers from
both pfspz-ga1 groups sterilely protected, remaining 17 22 showed
a patency ≥9 days (median patency controls, 7 days; range, 7 9). all
volunteers pfspz vaccine control group developed parasitemia (median
patency, 9 days; range, 7 12). immunized groups exhibited significant,
dose-related increase anti-pf circumsporozoite protein (csp) antibodies and
pf-specific interferon-γ (ifn-γ)-producing cells. although definite
conclusion drawn potential strength protective efficacy of
pfspz-ga1 vaccine, favorable safety profile induced immune responses by
pfspz-ga1 vaccine warrant clinical evaluation.

copyright © 2020 authors, rights reserved; exclusive licensee american
association advancement science. claim original u.s. government 
works.

doi: 10.1126/scitranslmed.aaz5629 
pmid: 32434847 

